A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-15

  Stott, Colin ^a   White, Linda ^a   Wright, Stephen ^a   Wilbraham, Darren ^b   Guy, Geoffrey ^a  

^a Porton Down Science Park   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Cannabidiol; Cytochrome P450; Delta 9 tetrahydrocannabinol; Nabiximols ; Sativex ; THC CBD spray

Indexed keywords

EID: 84878802805     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-236     Document Type: Article

References (30)

1. Bland TM, Haining RL, Tracy TS, Callery PS (2005) CYP2C-catalyzed delta(9)- tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 70:1096-103.
2. Chen J, Raymond K (2006) Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicriob 5:3.
3. Constantinescu CS, Sarantis N (2006) Long-term open-label treatment with Sativex® in patients with multiple sclerosis. Mult Scler 12:111.
4. Cupp MJ, Tracy TS (1998) Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 57:107-16.
5. DiPiro JT (1999) Pharmacotherapy: A Pathophysiologic Approach, 4th edn. Appleton & Lange, Stamford, Conn, pp 29-30.
6. Division of Clinical Pharmacology (2012) Indiana University Department of Medicine. Medicine.iupui.edu, http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed December 2012.
7. FDA Guidance for Industry (2012) Bioanalytical Method Validation issued by the U.S Department of Health and Human Services Food and Drug Administration, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed July 2012.
8. Federal Drug Association (2012) Drug development and drug interactions: table of substrates, inhibitors and inducers, http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed 25 April 2012.
9. Foltz RL, McGinnis KM, Chinn DM (1983) Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry. Biochemical MS 10(5):316-23.
10. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitorbased therapies. Drug Metab Pharmacokinet 20(3):153-167.
11. Goodall CR, Basteyns BJ (1995) A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood. J Anal Tox 19:419-426.
12. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21(1):70-83.
13. Howlett AC, Barth F, Bonner T et al (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161-202.
14. Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4:1770-804.
15. Johnson JR, Burnell-Nugent M, Lossignol D et al (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39(2):167-179.
16. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT (2012) An open-label extension study to investigate the long-term safety and tolerability of THC/ CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractive to strong opioid analgesia. J Pain Symptom Manage. doi:10.1016/j.jpainsymman.2012.07.014.
17. Kemp MP, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA (1995) Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Tox 19:91-285.
18. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260(4):984-997.
19. Michalets EL (1998) Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112.
20. Miller JC, Miller JN (1992) Statistics for analytical Chemistry. Ellis Horwood
21. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 133:210-20.
22. Ogu CC, Maxa JL (2000) Drug interactions due to cytochrome P450 Proc (Bayl Univ Med Cent) 13(4):421-423.
23. Pertwee RG (2007) Cannabinoids and Multiple Sclerosis. Mol Neurobiol 36:45-59.
24. Porteney R, Ganae-Motan ED, Allende S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438-449.
25. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 8:283-291.
26. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta-9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29(9):2068-2079.
27. Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoidterpenoid entourage effects. BJP 163:1344-1364.
28. Stott CG, White L, Wright S, Wilbraham D, Guy GW (2012) A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol. doi:10.1007/s00228-012-1441-0.
29. Whittle BA, Guy GW, Robson P (2001) Prospects for new cannabis-based prescription medicines. J Cannabis Therapeutics 1(3-4):183-205.
30. Yamaori S, Kushihara M, Yamamoto I, Watanabe K (2010) Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691-1698